Speaking to German radio Metropol FM, Merkel said Şahin and Türeci, who are married, made a foundational contribution to science with their company BioNTech, alongside U.S. pharmaceutical firm Pfizer.
Estimating that the BioNTech-Pfizer vaccine could be available in Europe at the beginning of January, Merkel said 70% of the population should be immunized to curb the outbreak.
“It will take months to vaccinate so many people. The elderly and healthcare professionals must first be protected. The second half of 2021 will have more vaccines, but considering the winter months, there will not be enough vaccines yet,” she said.
Merkel also urged citizens to comply with precautionary measures against the pandemic, especially in the winter.
Germany on Monday reported 147 more deaths from COVID-19, along with 12,332 cases.
The death toll now stands at 18,919 in the country, while 1.18 million have contracted the disease since the beginning of the pandemic.
Vaccine candidate BNT162b2, developed by BioNTech, has an efficacy of more than 94% in adults aged 65 and over, according to the results of Phase 3 clinical studies.
Last month, BioNTech and Pfizer submitted a request to the U.S. Food and Drug Administration for emergency use authorization of their vaccine candidate.
They have also initiated additional rolling submissions across the globe, including Australia, Canada and Japan, and plan to submit applications to other regulatory agencies around the world, according to the statement by the companies.
If regulatory approvals are obtained, BioNTech and Pfizer are planning to manufacture more than 50 million doses by the end of this year and potentially over 1.3 billion doses by the end of 2021.
Hurriyet Daily News